Itch associated with skin disease: Advances in pathophysiology and emerging therapies

American Journal of Clinical Dermatology

Volumn 4, Issue 9, 2003, Pages 617-622

  Yosipovitch, Gil ^a,b   Fleischer, Alan B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANESTHETIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPRURITIC AGENT; ARACHIDONIC ACID; BENZOCAINE; CALAMINE; CAMPHOR; CAPSAICIN; DERMATOLOGICAL AGENT; DOXEPIN; EMLA; IMMUNOMODULATING AGENT; NALFURAFINE; NALTREXONE; OPIATE ANTAGONIST; PRAMOCAINE; RECEPTOR BLOCKING AGENT; TACROLIMUS; THALIDOMIDE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; VANILLOID RECEPTOR;

ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FATIGUE; HUMAN; MULTICENTER STUDY; NEUROPATHOLOGY; NEUROPHYSIOLOGY; OINTMENT; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHOTOSTIMULATION; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURIGO; PRURITUS; PSORIASIS; SKIN DISEASE; TREATMENT INDICATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET IRRADIATION; VAGUS NERVE STIMULATION;

ADJUVANTS, IMMUNOLOGIC; ARACHIDONIC ACID; CAPSAICIN; ELECTRIC STIMULATION; HISTAMINE H1 ANTAGONISTS; HUMANS; NARCOTIC ANTAGONISTS; PHOTOTHERAPY; PRURITUS; SKIN DISEASES; THALIDOMIDE;

EID: 0141502514     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304090-00004     Document Type: Article

References (59)

1. Hafenreffer S. Nosodochium, inquocutis eique adaerentium partium affectus omnes singulari methodo et cognoscendi et curandi fidelisime traduntur. Ulmae Kuhnen 1660: 98-102
2. McMahon SB, Koltzenburg M. Itching for an explanation. Trends Neurosi 1992; 15: 497-501
3. Twycross R, Greaves MW, Handwerker H, et al. Itch: scratching more than the surface. Q J Med 2003; 56: 7-26
4. Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003; 361: 690-4
5. Bernhard JD. Neurogenic pruritus and strange sensations. In: Bernhard JD, editor. Itch mechanisms and management of pruritus. New York: McGraw Hill, 1994: 185-202
6. Rees JL, Laidlaw A. Pruritus: more scratch than itch. Clin Exp Dermatol 1999; 24: 490-3
7. Stangier U, Gieler U. Somatoform storungen in der dermatologie. Psychotherapie 1997; 2: 91-101
8. Wahlgren CF. Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol Suppl (Stockh) 1991; 165: 1-53
9. Beauregard S, Gilchrest BA. A survey skin problems and skin care regimens in the elderly. Arch Dermatol 1987; 123: 1638-43
10. Soter NA. Urticaria and angioedema. In: Freedberg IM, Eisen AZ, Wolff K et al., editors. Dermatology in general medicine. 5th ed. New York: McGraw Hill, 1998: 1409-19
11. Meding-B. Epidemiology of hand eczema in an industrial city. Acta Derm Venereol Suppl (Stockh) 1990; 153: 1-43
12. World Health Organization. WHO fact sheets on Onchocerciasis N-95, 2000
13. Bonacini M. Pruritus in patients with chronic human immunodeficiency virus, hepatitis B and C virus infections. Dig Liver Dis 2000; 32: 621-5
14. Rodwell GE, Berger TG. Pruritus and cutaneous inflammatory conditions in HIV disease. Clin Dermatol 2000; 18: 479-84
15. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4
16. Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969-73
17. Boyd AS, Nelder KH. Lichen planus. J Am Acad Dermatol 1991; 25: 593-619
18. Herman LE. Itching in scars. In: Bernhard J, editor. Itch mechanisms and management of pruritus. New York: McGraw Hill, 1994: 153-60
19. Schmelz M, Schmidt R, Bickel A, et al. Specific C receptors for itch in human skin. J Neurosci 1997; 17: 8003-8
20. Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001; 4: 72-7
21. Schmelz M. A neural pathway for itch. Nat Neurosci 2001; 4: 9-10
22. Hsieh JC, Hagermark O, Stahle-Backdahl M, et al. Urge to scratch represented in the human cerebral cortex during itch. J Neurophysiol 1994; 72: 3004-8
23. Darsow U, Drzezega A, Frisch M, et al. Processing of histamine: induced itch in the human cerebral cortex: a correlation analysis with dermal reactions. J Invest Dermatol 2000; 115: 1029-33
24. Drzezga A, Darsow U, Treede RD, et al. Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H2O positron emission tomography studies. Pain 2001; 92: 295-305
25. Hagermark O. Itch mediators. Semin Dermatol 1995; 14: 271-6
26. Heyer G, Hornstein O, Handwerker HO. Skin reactions and itch sensation induced by epicutaneous histamine application in atopic dermatitis and controls. J Invest Dermatol 1989; 93: 492-6
27. Heyer G, Ulmer FJ, Schmitz J, et al. Histamine: induced itch and alloknesis (itchy skin) in atopic eczema patients and controls. Acta Derm Venereol (Stockh) 1995; 75: 348-52
28. Wahlgren CF, Hagermark O, Bergstrom R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol 1990; 122: 545-51
29. Jarvikallio A, Naukkarinen A, Harvima IT, et al. Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema. Br J Dermatol 1997; 136: 871-7
30. Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteniase- activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000; 6: 151-8
31. Hagermark O. Study on experimental itch induced by Studies on experimental itch induced by kallikrein and bradykinin. Acta Derm Venereol 1974; 54: 397-400
32. Weidner C, Klede M, Rukwied R, et al. Acute effects of substance P and calcitonin gene-related peptide in human skin-a microdialysis study. J Invest Dermatol 2000; 115: 1015-20
33. Ballantyne JC, Loach AB, Carr DB. Itch after epidural and spinal opiates. Pain 1988; 33: 149-60
34. Bigliardi PL, Bigliardi-Qi M, Buechner S, et al. Expression of mu-opiate receptor in human epidermis and keratinocytes. J Invest Dermatol 1998; 111: 297-301
35. Stander S, Gunzer M, Metze D, et al. Localization of micro-opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept 2002; 110: 75-83
36. Handwerker HO. Opioids and itch [abstract]. In: Yosipovitch G. editor. International Workshop for the Study of Itch. Singapore: National Skin Center 2001; 42
37. Togashi Y, Umeuchi H, Okano K, et al. Antipruritic activity of kappa- opioid receptor agonist TRK-820. Eur J Pharmacol 2002; 435: 259-64
38. Yosipovitch G. Pruritus: an update. Curr Probl Dermatol 2003; 15: 143-64
39. Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol 1994; 31: 613-6
40. Shelley WB, Shelley ED, Talanin NY. Self potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. J Am Acad Dermatol 1996; 34: 143-4
41. Reimann S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001; 44: 471-8
42. Yosipovitch G, Maibach HI, Rowbotham MC. Effect of EMLA pre-treatment on capsaicin: induced burning and hyperalgesia. Acta Derm Venereol 1999; 79: 118-21
43. Miller MJ, Vergnolle N, McKnight W, et al. Inhibition of neurogenic inflammation by the Amazonian herbal medicine sangre de grado. J Invest Dermatol 2001; 117: 725-30
44. Yosipovitch G, Ademola J, Lui P, et al. Topically applied aspirin rapidly decreases histamine induced itch. Acta Derm Venereol 1997; 77: 46-8
45. Yosipovitch G, Sugeng MW, Chan YH, et al. The effect of topically applied aspirin on localized circumscribed neurodermatitis. J Am Acad Dermatol 2001; 45: 910-3
46. Watanabe T, Kuroda Y. The effect of a newly developed ointment containing eicosapentaenoic acid and docosahexaenoic acid in the treatment of atopic dermatitis. J Med Invest 1999; 46: 173-7
47. Yosipovitch G, David M. The diagnostic and therapeutic approach to idiopathic generalized pruritus. Int J Dermatol 1999; 38: 881-7
48. Fleischer AB. Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy. J Allergy Clin Immunol 1999; 104: S126-30
49. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002; 62: 817-40
50. Abeck D, Andersson T, Grosshans E, et al. Topical application of a platelet - activating factor (PAF) antagonist in atopic dermatitis. Acta Derm Venereol 1997; 77: 449-51
51. Zhai H, Hannon W, Hahn GS, et al. Strontium nitrate decreased histamine-induced itch magnitude and duration in man. Dermatology 2000; 200: 244-6
52. Daly MB, Shuster S. Antipruritic action of thalidomide. Acta Derm Venerol 2000; 80: 24-5
53. Calbarese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000; 108: 487-95
54. Stirling DI. Thalidomide and its impact in dermatology. Semin Cutan Med Surg 1998; 17 (4): 231-42
55. Metze D, Reimann S, Beissert S, et al. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal disease and dermatological diseases. J Am Acad Dermatol 1999; 41: 533-9
56. Kumagai H, Sasamura H, Hayashi M, et al. Prospects for a novel opioid kappa receptor agonist TRK 820 in uremic pruritus [abstract]. In: Yosipovitch, editor. International Workshop for the Study of Itch. Singapore: National Skin Center 2001 2001, 59
57. Nilsson HJ, Levinsson A, Schouenborg J. Cutaneous field stimulation (CFS): a new powerful method to combat itch. Pain 1997; 71: 49-55
58. Wallengren I, Sundler F. Cutaneous field stimulation in the treatment of severe itch. Arch Dermatol 2001; 137: 1323-5
59. Kirchner A, Stefan H, Schmelz M, et al. Influence of vagus nerve stimulation on histamine-induced itching. Neurology 2002; 59: 108-12